XTL Biopharmaceuticals Ltd (H2K2) — Financial Flexibility Index
XTL Biopharmaceuticals Ltd (H2K2) has a Financial Flexibility Index of -0.50x as of December 2024. Free cash flow of €-1.56 Million (operating CF €-1.62 Million minus capex €54.00K) represents -1% of total liabilities (€3.12 Million). Check how tangible is XTL Biopharmaceuticals Ltd's equity to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
XTL Biopharmaceuticals Ltd Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for XTL Biopharmaceuticals Ltd across 9 annual periods. For the full cash flow conversion analysis, see H2K2 cash flow conversion.
Annual Financial Flexibility Index for XTL Biopharmaceuticals Ltd (2016–2024)
Year-by-year free cash flow to debt coverage for XTL Biopharmaceuticals Ltd. Explore XTL Biopharmaceuticals Ltd (H2K2) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.50x | €-1.56 Million | €-1.62 Million | €3.12 Million | ▲ +85.4% |
| 2023 | -3.43x | €-707.00K | €-707.00K | €206.00K | ▲ +28.8% |
| 2022 | -4.82x | €-901.00K | €-901.00K | €187.00K | ▼ -490.2% |
| 2021 | -0.82x | €-1.05 Million | €-1.05 Million | €1.28 Million | ▲ +75.6% |
| 2020 | -3.34x | €-849.00K | €-850.00K | €254.00K | ▲ +14.4% |
| 2019 | -3.91x | €-906.00K | €-908.00K | €232.00K | ▼ -21.4% |
| 2018 | -3.22x | €-814.00K | €-816.00K | €253.00K | ▼ -750.0% |
| 2017 | -0.38x | €-1.12 Million | €-1.12 Million | €2.97 Million | ▲ +92.5% |
| 2016 | -5.05x | €-1.67 Million | €-1.73 Million | €330.00K | — |